Dong Kim's most recent trade in UroGen Pharma Ltd was a trade of 2,500 Restricted Stock Units done . Disclosure was reported to the exchange on Sept. 9, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 2,500 | 5,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 2,500 | 37,753 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Kim Dong | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 12,000 | 12,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Kim Dong | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 26,585 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Kim Dong | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 35,253 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 38,000 | 38,000 | - | - | Employee Stock Option (right to buy) | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| UroGen Pharma Ltd | Dong Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) |